These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 28078862

  • 1. A placebo-controlled trial of a proprietary lipid-lowering nutraceutical supplement in the management of dyslipidemia.
    Houston M, Rountree R, Lamb J, Phipps S, Meng S, Zhang B.
    J Biol Regul Homeost Agents; 2016; 30(4):1115-1123. PubMed ID: 28078862
    [Abstract] [Full Text] [Related]

  • 2. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
    Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J, CAP Investigators.
    Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
    [Abstract] [Full Text] [Related]

  • 3. Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial.
    Panahi Y, Khalili N, Sahebi E, Namazi S, Reiner Ž, Majeed M, Sahebkar A.
    Complement Ther Med; 2017 Aug; 33():1-5. PubMed ID: 28735818
    [Abstract] [Full Text] [Related]

  • 4. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ.
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [Abstract] [Full Text] [Related]

  • 5. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
    Hobbs T, Caso R, McMahon D, Nymark M.
    Altern Ther Health Med; 2014 Nov; 20(5):18-23. PubMed ID: 25141367
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J.
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [Abstract] [Full Text] [Related]

  • 7. Effect of Nigella sativa supplementation over a one-year period on lipid levels, blood pressure and heart rate in type-2 diabetic patients receiving oral hypoglycemic agents: nonrandomized clinical trial.
    Badar A, Kaatabi H, Bamosa A, Al-Elq A, Abou-Hozaifa B, Lebda F, Alkhadra A, Al-Almaie S.
    Ann Saudi Med; 2017 Dec; 37(1):56-63. PubMed ID: 28151458
    [Abstract] [Full Text] [Related]

  • 8. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R, Liu Y, Kwok S, Hama S, France M, Eatough R, Pemberton P, Schofield J, Siahmansur TJ, Malik R, Ammori BA, Issa B, Younis N, Donn R, Stevens A, Durrington P, Soran H.
    J Am Heart Assoc; 2015 Sep 15; 4(9):e001508. PubMed ID: 26374297
    [Abstract] [Full Text] [Related]

  • 9. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
    Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN.
    J Clin Lipidol; 2012 Sep 15; 6(6):565-72. PubMed ID: 23312052
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M, LCP-AtorFen Investigators.
    Clin Ther; 2009 Dec 15; 31(12):2824-38. PubMed ID: 20110022
    [Abstract] [Full Text] [Related]

  • 11. Ameliorating Effects of Four-Week Fiber-Multivitamin Combination Treatment on Low-Density Lipoprotein Cholesterol, Total Cholesterol, and Apolipoprotein B Profiles in Hypercholesterolemic Participants.
    Anggadiredja K, Ufamy N, Amalia L, Fisheri Kurniati N, Bahana Maulida Reyaan I.
    J Diet Suppl; 2020 Dec 15; 17(2):173-183. PubMed ID: 30380357
    [Abstract] [Full Text] [Related]

  • 12. Garlic powder, effect on plasma lipids, postprandial lipemia, low-density lipoprotein particle size, high-density lipoprotein subclass distribution and lipoprotein(a).
    Superko HR, Krauss RM.
    J Am Coll Cardiol; 2000 Feb 15; 35(2):321-6. PubMed ID: 10676676
    [Abstract] [Full Text] [Related]

  • 13. Randomized double blind clinical trial on the effect of oral α-cyclodextrin on serum lipids.
    Amar MJ, Kaler M, Courville AB, Shamburek R, Sampson M, Remaley AT.
    Lipids Health Dis; 2016 Jul 12; 15(1):115. PubMed ID: 27405337
    [Abstract] [Full Text] [Related]

  • 14. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS, Milionis HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, Elisaf MS.
    Clin Ther; 2007 Jul 12; 29(7):1403-14. PubMed ID: 17825691
    [Abstract] [Full Text] [Related]

  • 15. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.
    Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour-Mobarhan M, Ferns GA.
    Phytother Res; 2013 Mar 12; 27(3):374-9. PubMed ID: 22610853
    [Abstract] [Full Text] [Related]

  • 16. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects.
    Cicero AF, Derosa G, Parini A, Maffioli P, D'Addato S, Reggi A, Giovannini M, Borghi C.
    Nutr Res; 2013 Aug 12; 33(8):622-8. PubMed ID: 23890351
    [Abstract] [Full Text] [Related]

  • 17. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 12; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 18. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC, Davidson MH, Kelly MT, Setze CM.
    Am J Cardiovasc Drugs; 2012 Apr 01; 12(2):117-25. PubMed ID: 22263674
    [Abstract] [Full Text] [Related]

  • 19. LDL-cholesterol lowering effect of a new dietary supplement: an open label, controlled, randomized, cross-over clinical trial in patients with mild-to-moderate hypercholesterolemia.
    Magno S, Ceccarini G, Pelosini C, Jaccheri R, Vitti J, Fierabracci P, Salvetti G, Airoldi G, Minale M, Saponati G, Santini F.
    Lipids Health Dis; 2018 May 24; 17(1):124. PubMed ID: 29793488
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G, Di Garbo V, Guarnotta V, Scaglione R, Parrinello G, Purpura L, Torres D, Campisi D.
    Int Angiol; 2010 Dec 24; 29(6):514-24. PubMed ID: 21173733
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.